Sign in
Not yet recruitingPhase 2

Methotrexate compared with acitretin for widespread lichen planus

Compares methotrexate and acitretin tablets in adults with generalized lichen planus.

Key facts

Who runs it
Sheikh Zayed Medical College
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Systemic Treatment Options for Generalized Lichen Planus
Status
Not yet recruiting
Phase
Phase 2
People taking part
124 people, planned
Started
10 Dec 2024
Planned end
20 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methotrexate (drug)
  • Acitretin
Record updated
18 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with generalized lichen planus, a long-lasting skin inflammation spread over the body. It compares oral methotrexate with oral acitretin.

Age
18 to 60 years
Sex
Men and women
Disease stage
Generalized lichen planus
Earlier treatment
People cannot have taken treatment in the last 1 month.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Bleeding disorders
  • Abnormal liver function tests or platelet count less than 100000
  • Allergy to Methotrexate or Acitretin
  • Unrealistic expectations

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age: 18-60 years
  • Gender: both male and female
  • Type of Lichen planus: generalized lichen planus
  • Patients not taking prior treatment in last 1 month

Who cannot take part

  • Bleeding disorders
  • Hypersensitivity to Methotrexate or Acitretin
  • Platelet count less than 100000
  • Pregnancy and lactating females
  • Abnormal liver function tests
  • Unrealistic expectations

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Lichen planus is a chronic inflammatory skin condition with unknown etiology. It requires a long term treatment. Evaulating the most efficacious, safe and affordable treatment option is the need of the hour. This study is going to compare the efficacy of two familiar drugs (acitretin and methotrexate) in the treatment of generalized lichen planus as to find out the relatively more effective and safer treatment.

The 2 groups in the trial

  • Oral methotrexate group (Group A)Existing treatment, for comparison

    Patients with generalized lichen planus will be given 10 mg per week

    Treatment: Methotrexate (drug)

  • Oral Acitretin group (Group B)Existing treatment, for comparison

    Patients with generalized lichen planus will be given oral acitretin 50 mg once daily

    Treatment: Acitretin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Efficacy of Oral Methotrexate and Acitretin for Generalized Lichen Planus
Plain-language title
Methotrexate compared with acitretin for widespread lichen planusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06739551, who can take part
Record updated
18 December 2024